Related Experiment Video
Updated: May 12, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Impact of MEK Inhibition on Childhood RASopathy-Associated Hypertrophic Cardiomyopathy
Cordula M Wolf1, Martin Zenker2, Olga Boleti3
1Department of Congenital Heart Defects and Pediatric Cardiology, German Heart Center Munich, School of Medicine and Health, Technical University of Munich, Munich, Germany; Deutsches Zentrum für Herz-Kreislauf-Forschung (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; Member of the European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart.
Mitogen-activated protein kinase kinase inhibition shows promise in treating severe hypertrophic cardiomyopathy in children with RASopathy. This targeted therapy improved cardiac status and reduced mortality compared to standard care.
Area of Science:
- Pediatric Cardiology
- Molecular Biology
- Genetics
Background:
- Severe hypertrophic cardiomyopathy in children with RASopathy leads to heart failure and death.
- There is a critical need for effective treatments for this condition.
- RAS/mitogen-activated protein kinase pathway variants are implicated in pediatric hypertrophic cardiomyopathy.
Purpose of the Study:
- To evaluate the efficacy of mitogen-activated protein kinase kinase (MAP2K) inhibition in children with RASopathy and severe hypertrophic cardiomyopathy.
- To compare outcomes between patients receiving MAP2K inhibition and those receiving standard care.
Main Methods:
- Retrospective analysis of 61 pediatric patients with RASopathy and severe hypertrophic cardiomyopathy.
- Comparison of outcomes in 30 patients treated with MAP2K inhibition versus 31 patients receiving standard-of-care treatment.
Main Results:
- MAP2K inhibition was associated with decreased mortality and morbidity.
- Patients receiving MAP2K inhibition showed improved cardiac status compared to the standard-of-care group.
- Reported side effects were manageable and not life-threatening.
Conclusions:
- Personalized therapies targeting signaling pathway abnormalities, such as MAP2K inhibition, may be effective for critically ill pediatric patients with RASopathy.
- Clinical investigation of MAP2K inhibition for severe hypertrophic cardiomyopathy in RASopathy is warranted.
More Related Videos
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
09:58An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence
Published on: May 2, 2025
Related Concept Videos
Mitogens and the Cell Cycle
Abnormal Proliferation
The Ras Gene
Ras is a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
MAPK Signaling Cascades